605116 Aurisco Pharmaceutical
- 21.50
- +0.42+1.99%
Aurisco Pharmaceutical News
Orient (605116.SH) will pay 0.22 yuan per share in 2023. The stock registration date is June 5
Orient (605116.SH) issued an announcement. The company will implement the 2023 annual equity distribution, and each share will be distributed to discover...
Express News | Orient: Synthetic biology has been applied to products such as simeglutide and remegipam
Orient (605116): Performance showed rapid growth, and didroprogesterone preparations gradually contributed to the increase in core performance
Incident Overview (1) Company Announcement 2023 Annual Report: 23 Achieved annual revenue of 1,263 billion yuan, a year-on-year increase of 25.24%, and realized net profit to mother of 289 million yuan, an increase of 37.19% year-on-year, and realized deductions
Orient (605116): Integrated API formulation breaks through production capacity release to ensure future growth
Core view The company's revenue and profit continued to grow rapidly in 2023, and 24Q1 profit growth exceeded expectations. In terms of APIs, cardiovascular and anti-tumor drugs are developing rapidly, and within 23 years, the company has achieved a breakthrough in the integration of API formulations.
Orient (605116): Barrier varieties continue to increase in volume profits
Key investment performance: 2023&2024Q1 profit growth was high, and the company's revenue in 2023 was 1,263 million yuan (YOY 25.24%), and net profit to mother was 289 million yuan (YOY 37.19%).
Orient (605116): The API business is growing steadily, and didroprogesterone tablets open a new chapter in formulation
Event: On April 29, 2024, the company released its 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved operating income of 1,263 billion yuan, a year-on-year increase of 25.24%, and net profit to mother 2.
Orient (605116): Q1 performance exceeds market expectations and is optimistic about the accelerated release of the formulation and peptide business
Incident: On April 28, 2024, the company released its 2023 annual report. In 2023, the company achieved operating income of 1,263 million yuan (YoY +25.24%) and net profit of 289 million yuan (Yo
Orient (605116.SH) announced its 2023 annual results, net profit of 289 million yuan increased 37.19% year over year
Orient (605116.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 12...
Insiders the Biggest Winners as Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Market Cap Rises to CN¥9.3b
Key Insights Insiders appear to have a vested interest in Aurisco PharmaceuticalLtd's growth, as seen by their sizeable ownership The top 2 shareholders own 70% of the company Using data from comp
Pacific Securities: The API industry is in the de-inventory phase or nearing its end, and the 24-year sector is expected to usher in a beta market
The Zhitong Finance App learned that Pacific Securities released a research report saying that in December 2023, production of chemical raw materials by industrial enterprises above the Chinese scale began to resume growth, with a year-on-year increase of 2% and a month-on-month increase of 35%. From January to February 2024, production was 546,000 tons. Although the year-on-year decline was 7.6%, it has already exceeded the same period in 2021 and 2022, continuing the improvement at the end of 2023. As major product patents expire one after another and overseas inventory removal gradually comes to an end, the demand side of the API sector is expected to gradually pick up in 2024, ushering in a beta market. Recommended attention: 1) Continued direction in 2024
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Aurisco PharmaceuticalLtd's (SHSE:605116) recent performance, when its stock has declined 14% over the past three months. However, a closer look at its sou
Aurisco PharmaceuticalLtd (SHSE:605116) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
“Jia Ling Lose Weight” has been trending for 4 days in a row. Will the number one investment theme in the Year of the Dragon be a comeback of the diet pill concept?
Under the popularity of the topic, the market speculates: will diet pills become the first investment theme in the Year of the Dragon?
Subdued Growth No Barrier To Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Price
With a price-to-earnings (or "P/E") ratio of 36.1x Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E
Orient (605116.SH): The application to issue convertible bonds was reviewed and approved by the Shanghai Stock Exchange Listing Review Committee
Glonghui, January 23 | Orient (605116.SH) announced that the Shanghai Stock Exchange Listing Review Committee held the 5th 2024 Listing Review Committee Review Meeting on January 23, 2024 to review the company's application to issue convertible corporate bonds to unspecified targets. According to the review results of the meeting, the company's application to issue convertible corporate bonds to unspecified targets met the issuance conditions, listing conditions and information disclosure requirements.
Orient (605116.SH): Wholly-owned subsidiary approved as a high-tech enterprise
Glonghui, January 11 | Orient (605116.SH) announced that Orient Pharmaceutical (Tianjin) Co., Ltd. (known as “Tianjin Orient”), a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Tianjin Municipal Bureau of Science and Technology, the Tianjin Municipal Finance Bureau, and the Tianjin Municipal Taxation Bureau of the State Administration of Taxation. Certificate number: GR202312001758, issuance time: December 8, 2023, validity period: three years. This is the first time that Tianjin Orient has been certified as a high-tech enterprise.
Orient (605116.SH): The existing 100-ton pregabalin API production line is in Tiantai, Taizhou
Glonghui, January 9 | Orient (605116.SH) said on the investor interactive platform that the company's current 100-ton pregabalin API production line is in Tiantai, Taizhou. Considering site certification and improving production management efficiency, the company built a 300.60 ton pregabalin API production line at the new plant in Cangshan, Taizhou.
Insiders the Biggest Winners as Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Market Cap Rises to CN¥11b
Key Insights Aurisco PharmaceuticalLtd's significant insider ownership suggests inherent interests in company's expansion 70% of the business is held by the top 2 shareholders Ownership research,
Does Aurisco PharmaceuticalLtd (SHSE:605116) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But the reality is that when a company lo
Orient (605116) 2023 Three Quarterly Report Review: API Business Is Heightened, Droghedrone Tablets Are Rapidly Releasing
Orient has built a leading R&D and production platform for small molecules, peptides and oligonucleotide drugs, gradually extending from APIs and intermediates to formulations, and has established 6 covering the respiratory system, cardiovascular system, anti-infection, neurological system, anti-tumor, and women's health
Analysis
Price Target
No Data
